Fundamentals of HIV Medicine 2019W. David Hardy Oxford University Press, 2019 - 584 Seiten The essential work in HIV for providers and pharmacists -- updated with everything they need to know in 2019! Assembled by the leading educational organization in HIV medicine, AAHIVM's Fundamentals of HIV Medicine 2019 is an end-to-end clinical resource for the treatment of individuals with HIV/AIDS. It offers state-of-the-art practical advice for physicians, pharmacists, nurse practitioners, and other professionals working in the care of HIV patients. Along with updates to the classic domains of HIV medicine, this new edition features expanded coverage of emerging topics, including: behavioral and therapeutic interventions to HIV prevention; updates on the pursuit of a cure; new DHHS and IAS guidelines and their clinical implications; and the myriad issues around aging with HIV. Embodying the American Academy of HIV Medicine's commitment to excellence in the care of seropositive patients, Fundamentals of HIV Medicine 2019 is must-have for health professionals across HIV care, treatment, and prevention. |
Inhalt
1 Epidemiology and the Spread of HIV | 1 |
2 The Origin Evolution and Epidemiologyof HIV 1 and HIV 2 | 15 |
3 Mechanisms of HIV Transmission | 21 |
4 HIV Transmission Prevention | 25 |
5 Immunology | 49 |
6 HIV Cure Strategies | 59 |
7 HIV Testing and Counseling | 67 |
8 Laboratory Testing Strategies Detectionand Diagnosis | 73 |
28 Antiretroviral Therapy for Children and Newborns | 287 |
29 Immunosuppressants and Antiretroviral Therapyin HIV Positive Transplant Patients | 297 |
30 Understanding and Managing Antineoplastic andAntiretroviral Therapy | 301 |
31 Substance Abuse in HIV Populations | 309 |
32 Understanding the Use of Antiretrovirals in theAging Patient | 317 |
33 Opportunistic Infections | 323 |
34 Malignant Diseases in HIV | 337 |
35 Dermatologic Complications | 379 |
9 The Medical History and Physical Examination ofthe Patient with HIV | 83 |
10 Initial Laboratory Evaluation and Risk Stratificationof the Patient with HIV | 87 |
11 Recognition of Acute and Advanced HIV Infection | 91 |
12 Health Maintenance | 97 |
13 Issues in Specific Patient Populations | 115 |
14 Complementary and AlternativeMedicine Integrative Medicine Approaches | 157 |
15 HIV Care Coordination | 175 |
16 The Pharmacists Role in Caring forHIV Positive Individuals | 183 |
17 The Role of the Physician Assistant and the NursePractitioner in Caring for Persons Living with HIV | 189 |
18 Hospice and Palliative Care in AdvancedHIV Disease | 199 |
19 HIV Virology | 205 |
20 Principles of Applied Clinical Pharmacokineticsand Pharmacodynamics in Antiretroviral Therapy | 219 |
21 Classes of Antiretrovirals | 225 |
Whatto Start With | 239 |
23 HIV 1 Resistance to Antiretroviral Drugs | 245 |
24 Managing the Patient with Multidrug Resistant HIV | 257 |
25 Future Antiretrovirals Immune Based Strategiesand Therapeutic Vaccines | 261 |
26 Solid Organ Transplantation in Persons Livingwith HIV | 275 |
27 Antiretroviral Therapy in Pregnant Women | 281 |
36 Endocrine and Metabolic Disorders | 391 |
RespiratoryComplications | 399 |
38 Psychiatric Illness and Treatment inHIV Populations | 403 |
39 Neurological Effects of HIV Infection | 413 |
40 HIV and Hepatitis Coinfection | 433 |
41 Ocular Complications | 447 |
42 Cardiovascular Disease | 453 |
43 Renal Complications | 469 |
44 Body Composition Changes Frailty andMusculoskeletal Complications of HIV | 481 |
45 Sexually Transmitted Diseases | 487 |
46 HIV and Bone Health | 493 |
47 HIV Associated Lipodystrophy and Lipoatrophy | 505 |
48 Immune Reconstitution InflammatorySyndrome IRIS | 513 |
49 US Healthcare Systems HIV Programs andCoverage Policy Issues | 519 |
50 Legal Issues | 525 |
51 Research Design and Analysis | 541 |
52 Ethical Conduct of Clinical Trials InstitutionalReview Boards Informed Consent and FinancialConflicts of Interest | 545 |
| 549 | |
Andere Ausgaben - Alle anzeigen
Häufige Begriffe und Wortgruppen
abacavir Accessed active acute adolescents adults agents AIDS anal antibody antiretroviral drugs antiretroviral therapy associated atazanavir Available CD4+ T cell cell count cervical chronic Clin Infect clinical trials cohort coinfected darunavir decreased diagnosis dolutegravir dose drug interactions efavirenz effects efficacy emtricitabine evaluated guidelines HAART Health healthcare hepatitis HIV infection HIV patients HIV testing HIV transmission HIV-positive human immunodeficiency virus immune incidence increased risk infected patients initial integrase integrase inhibitors lamivudine Lancet lesions levels liver living with HIV lymphoma medications metabolic mutations NNRTIs NRTIs Opportunistic Infections outcomes patients with HIV pharmacokinetic PLWH population positive patients PrEP prevalence prophylaxis raltegravir randomized rates recommended reduce regimens renal resistance retinitis reverse transcriptase inhibitors rilpivirine risk factors ritonavir screening sexual symptoms syndrome tenofovir tion toxicity transgender transplant treatment USDHHS vaccine viral load virologic women zidovudine
